Table 1 Literature review
From: Modelling prognostic factors in advanced pancreatic cancer
Type (number) of studies | Number of patients per study | Prognostic factors reported (frequency of reporting) | U or MV analysis | ||
|---|---|---|---|---|---|
Randomised controlled trial (n=4)3–6 | 207–322 | Surgical | Metastases | (3) | 4 MV |
| Â | Â | Â | Tumour location | (1) | Â |
| Â | Â | Clinical | Performance status | (3) | Â |
| Â | Â | Â | Treatment | (1) | Â |
| Â | Â | Laboratory | Alkaline phosphatase | (1) | Â |
Consecutive series >500 patients (n=3)7–9 | 782–2380 | Surgical | Metastases | (1) | 2 MV |
| Â | Â | Â | Stage of disease | (1) | 1 U |
| Â | Â | Â | Operation | (1) | Â |
| Â | Â | Clinical | Performance status | (1) | Â |
| Â | Â | Â | Diabetes | (1) | Â |
| Â | Â | Â | Pain | (1) | Â |
| Â | Â | Â | Appetite/weight | (1) | Â |
| Â | Â | Â | Jaundice | (1) | Â |
| Â | Â | Â | Treatment | (1) | Â |
| Â | Â | Laboratory | Albumin | (1) | Â |
| Â | Â | Demographic | Age | (1) | Â |
| Â | Â | Â | Specialist centre | (1) | Â |
Consecutive series 100–500 patients (n=14)10–23 | 102–450 | Surgical | Metastases | (4) | 13 MV |
| Â | Â | Â | Stage of disease | (2) | 1 U |
| Â | Â | Â | Tumour location | (1) | Â |
| Â | Â | Â | Operation | (2) | Â |
| Â | Â | Â | Tumour size | (1) | Â |
| Â | Â | Â | Duodenal invasion | (1) | Â |
| Â | Â | Â | Peridissemination | (1) | Â |
| Â | Â | Â | Ascites | (1) | Â |
| Â | Â | Clinical | Performance status | (2) | Â |
| Â | Â | Â | Diabetes | (1) | Â |
| Â | Â | Â | Pain | (1) | Â |
| Â | Â | Â | Appetite/weight | (3) | Â |
| Â | Â | Â | Symptom onset | (1) | Â |
| Â | Â | Â | Treatment | (2) | Â |
| Â | Â | Laboratory | CA242 | (2) | Â |
| Â | Â | Â | CA19-9 | (2) | Â |
| Â | Â | Â | Leukocytes | (1) | Â |
| Â | Â | Â | Gamma GT | (1) | Â |
| Â | Â | Â | Albumin | (1) | Â |
| Â | Â | Â | LDH | (1) | Â |
| Â | Â | Â | CRP | (3) | Â |
| Â | Â | Â | Iron | (1) | Â |
| Â | Â | Demographic | Age | (1) | Â |
Consecutive series | 28–95 | Surgical | Metastases | (1) | 8 MV |
<100 patients (n=15)24–38 |  |  | Stage of disease | (1) | 7 U |
| Â | Â | Â | Grade of disease | (1) | Â |
| Â | Â | Â | Nodal status | (1) | Â |
| Â | Â | Â | Operation | (1) | Â |
| Â | Â | Â | Tumour size | (2) | Â |
| Â | Â | Â | Fibrosis | (1) | Â |
| Â | Â | Clinical | Performance status Inflammation | (4) | Â |
| Â | Â | Â | Appetite/weight | (1) | Â |
| Â | Â | Â | Treatment | (1) | Â |
| Â | Â | Laboratory | CA19-9 | (1) | Â |
| Â | Â | Â | VEGF | (7) | Â |
| Â | Â | Â | CEA | (1) | Â |
| Â | Â | Â | Phase angle BIA | (1) | Â |
| Â | Â | Â | SCA | (1) | Â |
| Â | Â | Â | Â | (1) | Â |